A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Cytomegalovirus vaccine vCP260 (Primary)
- Indications Cytomegalovirus infections
- Focus Pharmacodynamics
- 17 Dec 2009 Actual patient number (38) added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 17 Oct 2008 New trial record.